Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
| ▸ | USP7 | Q93009 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22924111 | 0.86 | MAPK1 (0.36) | ADRA2AGRM4NOS3NOS2MAPK1 | |
| SCHEMBL25702356 | 0.80 | NOS3 (0.35) | NOS3NOS2MAPK1 | |
| SCHEMBL25667671 | 0.80 | ADRA2A (0.38) | ADRA2AGRM4MAPK1MCHR1 | |
| SCHEMBL24322401 | 0.77 | NOS2 (0.44) | NOS3NOS2NTRK1 | |
| SCHEMBL22328047 | 0.77 | NOS3 (0.33) | NOS3NOS2MAPK1 | |
| SCHEMBL23588699 | 0.77 | NOS3 (0.33) | GRM4NOS3NOS2MAPK1 | |
| SCHEMBL22328045 | 0.74 | ADRA2A (0.35) | ADRA2AGRM4MAPK1 | |
| SCHEMBL25696136 | 0.74 | MAPK1 (0.36) | ADRA2AGRM4MAPK1MCHR1 | |
| SCHEMBL25702607 | 0.72 | TLR8 (0.31) | GRM4NOS3NOS2 | |
| SCHEMBL19115954 | 0.71 | JAK2 (0.41) | NOS3NOS2MAPK1NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639346-B2 | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS | ARAXES PHARMA LLC (US) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639346-B2 | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS | KRAS, NRAS, HRAS | ADRA2A 392/4885GRM4 3480/4885NOS3 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.